^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tolinapant (ASTX660)

    i
    Company:
    Otsuka
    Drug class:
    XIAP antagonist, cIAP1 antagonist, cIAP2 antagonist
    Related drugs:
    Apply
    Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/06/2025
    Initiation :
    08/04/2025
    Primary completion :
    05/17/2027
    Completion :
    05/17/2027
    RIPK1
    |
    Halaven (eribulin mesylate) • tolinapant (ASTX660)